相信通过菠菜担保网与亿胜生物的相助， ，，，HLX04-O有望成为首批获得批准用于眼科相关疾病治疗的贝伐珠单抗， ，，，惠及全球众多眼科疾病患者。 。。未来， ，，，菠菜担保网也将一连引领立异生物药品的开发， ，，，依附已经建设起的完善的立异研发平台， ，，，一连高效地为全球患者提供可肩负的、疗效更好的治疗计划。 。。
关于HLX04-O
HLX04-O是菠菜担保网在自主研发的贝伐珠单抗生物类似药HLX04的基础上， ，，，凭证眼科用药的需求对HLX04的处方、规格和生产工艺举行优化， ，，，在活性成份稳固的基础上， ，，，开发的新的眼科制剂产品， ，，，拟用于wAMD的治疗。 。。通过可比性研究批注生产工艺和制剂处方的变换对药物制剂的质量、清静性和有用性未爆发倒运影响。 。。HLX04-O主要作用机制为：通过抑制VEGF与其位于内皮细胞上的受体Flt-1和KDR相连系， ，，，抑制其酪氨酸激酶信号通路激活， ，，，抑制内皮细胞增生， ，，，镌汰新生血管天生， ，，，从而治疗血管增生眼部疾病。 。。
参考文献
[1] 欧阳灵艺, 邢怡桥. 抗VEGF药物在湿性年岁相关性黄斑变性中的应用希望[J]. 国际眼科杂志, 2020(1).
[2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51.
[3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106-116.
[4] Li X R , Liu J P . Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292.
[5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomized double masked study. BMJ. 2010 Jun 9;340:c2459.
[6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908.
[7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411.
[8] Kodjikian L, Souied EH, Mimoun G, Mauget-Fa?sse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Agerelated Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9.
[9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Sch?nherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.
[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52.
[11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG,Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5):e0153052.